Oculis Holding AG (NASDAQ: OCS) announced that its Phase 3 DIAMOND trials of OCS-01 eye drops for diabetic macular edema ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE